

ACHILLION PHARMACEUTICALS INC

Form 8-K

February 09, 2015

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**WASHINGTON, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**  
**PURSUANT TO SECTION 13 OR 15(d)**  
**OF THE SECURITIES EXCHANGE ACT OF 1934**

**Date of Report (Date of earliest event reported): February 9, 2015**

**Achillion Pharmaceuticals, Inc.**

**(Exact name of Registrant as Specified in Charter)**

**Delaware**  
**(State or other jurisdiction)**

**001-33095**  
**(Commission)**

**52-2113479**  
**(IRS Employer)**

**of incorporation)**

**File Number)**

**Identification No.)**

**300 George Street**

**New Haven, CT**

**(Address of principal executive offices)**

**06511**

**(Zip Code)**

**Registrant's telephone number, including area code: (203) 624-7000**

**(Former Name or Former Address, if Changed Since Last Report)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 8.01. Other Events.**

On February 9, 2015, Achillion Pharmaceuticals, Inc. (the Company) issued a press release announcing updated interim results from the Company's ongoing Phase 2 study to evaluate the efficacy, safety, and tolerability of eight- and six-week regimens of ACH-3102, an NS5A inhibitor, and sofosbuvir, a marketed nucleotide polymerase inhibitor, in treatment-naïve genotype 1 HCV-infected patients. The full text of the press release issued in connection with this announcement is attached as Exhibit 99.1 and incorporated herein by reference.

**Item 9.01. Financial Statements and Exhibits**

(d) Exhibits

**Exhibit**

<b>No.</b>	<b>Description</b>
99.1	Press Release of the Company dated February 9, 2015.

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**Achillion Pharmaceuticals, Inc.**

Date: February 9, 2015

By: /s/ Mary Kay Fenton  
Mary Kay Fenton  
Executive Vice President and Chief Financial Officer

**Exhibit Index**

**Exhibit**

<b>No.</b>	<b>Description</b>
99.1	Press Release of the Company dated February 9, 2015.